Scientifically proven.
Research
Study 2019
The scientifically proven effectiveness of FIBRILIUM® was demonstrated in a clinical study by DDr. Michael Ofner. In 2019, DDr. Ofner received the “ITALIAN HEALTH AWARD 2019” for his achievements in health promotion and regeneration research. Thanks to ifibr®, numerous users around the world are enjoying better sleep and improved health. ifibr® is a reliable and efficient solution for improving your well-being while you sleep.
FIBRILIUM® becomes FIBRANIUM®
Study 2024
In 2024, another study was conducted under the direction of DDr. Michael Ofner after the fiber had been further developed. The new fiber, called “FIBRANIUM®,” with an improved composition and manufacturing process, was also clinically tested and delivered even more impressive results.
The research results show that FIBRANIUM® has been proven to improve health-related quality of life and is recognized as a non-drug therapy option for chronic back pain.
Study design
This is a prospective, randomised, double-blind, placebo-controlled study led by DDr. Michael Ofner. The study protocol and the inclusion and exclusion criteria were approved by the Carinthian Ethics Committee on 30 January 2024.
The patients were recruited from a general practice and a physiotherapy clinic in Klagenfurt, Austria, and were examined and monitored by the investigator, DDr. Martin Liebhauser, over the 4-week test period. The participants were randomised and received either a FIBRANIUM® topper or a placebo topper for four weeks. To ensure compliance with the programme, participants were regularly monitored and recorded their progress using an online self-monitoring questionnaire.
The order of allocation was concealed from both the patients and the investigator, ensuring double-blinding. Blinding was maintained throughout the study, including during data collection and analysis.
University of Pisa
During the evaluation phase of the study, an analysis of the FIBRANIUM® fibre was carried out at the University of Pisa in August 2024. The material testing using CNR measurement confirms the special properties of ifibr®. Details and the report from Pisa can be found in the CNR measurement category.
Results
Based on the clinical baseline characteristics of the two groups, as well as the baseline values and results after the test phase, the FIBRARNIUM® group showed statistically significant greater improvements in several measurements compared to the placebo group.
These results are consistent with and extend our previous studies on the FIBRILIUM® fibre. In particular, the effects observed in the current study with FIBRARNIUM® appear to be even greater than those observed with FIBRILIUM® for several key outcome measures, suggesting that the modifications incorporated into the FIBRARNIUM® fibre, such as additional crystalline minerals and a modified manufacturing process, have improved its therapeutic properties.
Brief description:
As a recognised Class 1 medical device, ifibr® has been proven to improve pain relief and related parameters with the help of the FIBRARNIUM® fibre.
